EUVIMEDEUVIMED entdecken
Crossref

NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models

Xinyi Qiao, Ke Zheng, Lei Ye, Jin Yang, Rong Cui, Yuanyuan Shan, Xiaoheng Li, Huitao Li, Qiqi Zhu, Zhiguang Zhao, Ren-Shan Ge iD, Yiyan Wang

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Xinyi Qiao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University,…. Hauptthemen laut MEDLINE: Apoptosis, Prostatic Neoplasms, Protein Serine-Threonine Kinases, Curcumin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Prostate cancer remains a major public health burden worldwide. Polo like kinase 4 (PLK4) has emerged as a promising therapeutic target in prostate cancer due to its key roles in cell cycle regulation and tumour progression. This study aims to develop and characterize the novel curcumin analogue NL13 as a potential therapeutic agent and PLK4 inhibitor against prostate cancer. Experimental Approach NL13 was synthesized and its effects were evaluated in prostate cancer cells and mouse xenograft models. Kinome screening and molecular modelling identified PLK4 as the primary target. Antiproliferative and proapoptotic mechanisms were explored via cell cycle, apoptosis, gene and protein analyses. Key Results Compared with curcumin, NL13 exhibited much greater potency in inhibiting PC3 (IC 50 , 3.51 μM vs. 35.45 μM) and DU145 (IC 50 , 2.53 μM vs. 29.35 μM) prostate cancer cells viability and PLK4 kinase activity (2.32 μM vs. 246.88 μM). NL13 induced G2/M cell cycle arrest through CCNB1/CDK1 down‐regulation and triggered apoptosis via caspase‐9/caspase‐3 cleavage. These effects were mediated by PLK4 inhibition, which led to the inactivation of the AKT signalling pathway. In mice, NL13 significantly inhibited tumour growth and modulated molecular markers consistent with in vitro findings, including decreased p‐AKT and increased cleaved caspase‐9/3. Conclusion and Implications NL13, a novel PLK4‐targeted curcumin analogue, exerts promising anticancer properties against prostate cancer by disrupting the PLK4‐AKT‐CCNB1/CDK1 and apoptosis pathways. NL13 represents a promising new agent for prostate cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisProstatic NeoplasmsProtein Serine-Threonine KinasesCurcuminAntineoplastic AgentsCell Cycle CheckpointsMaleHumansAnimalsMiceMice, NudeCell ProliferationProtein Kinase InhibitorsCell Line, TumorDose-Response Relationship, DrugMice, Inbred BALB C

Stichwörter der Autor:innen

apoptosiscell cyclecurcumin analoguepolo like kinase 4prostate cancer

Substanzen

Protein Serine-Threonine KinasesCurcuminAntineoplastic AgentsPLK4 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Key Laboratory of Pediatric Anesthesiology, Ministry of Education, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Key Laboratory of Anesthesiology of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Key Laboratory of Environment and Male Reproductive Medicine of Wenzhou, Wenzhou, Zhejiang, China.
  • Department of Pathology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

ORCID-Profile: Ren-Shan Ge

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Qiao, X., Zheng, K., Ye, L., Yang, J., Cui, R., Shan, Y., Li, X., Li, H., Zhu, Q., Zhao, Z., Ge, R. S., & Wang, Y. (2024). NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models. British Journal of Pharmacology. https://doi.org/10.1111/bph.16501

Vancouver

Qiao X, Zheng K, Ye L, Yang J, Cui R, Shan Y, et al. NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models. British Journal of Pharmacology. 2024. doi:10.1111/bph.16501

BibTeX
@article{Qiao2024,
  author = {Qiao, Xinyi and Zheng, Ke and Ye, Lei and Yang, Jin and Cui, Rong and Shan, Yuanyuan and Li, Xiaoheng and Li, Huitao and Zhu, Qiqi and Zhao, Zhiguang and Ge, Ren-Shan and Wang, Yiyan},
  title = {NL13, a novel curcumin analogue and polo like kinase 4 inhibitor, induces cell cycle arrest and apoptosis in prostate cancer models},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16501}
}
Kostenlos starten →